ArticlemAbs2025

Preclinical development of ozuriftamab vedotin (BA3021), a novel ROR2-specific conditionally active biologic antibody-drug conjugate.

Hwai Wen Chang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.